We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Pain Outcomes Following Intralesional Corticosteroid Injections

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03630198
Recruitment Status : Completed
First Posted : August 14, 2018
Results First Posted : March 11, 2021
Last Update Posted : March 11, 2021
Information provided by (Responsible Party):
Brian Drolet, Vanderbilt University Medical Center

Brief Summary:

Corticosteroid therapy, including intralesional and topical applications, has many indications within the fields of Dermatology, Plastic Surgery, and Orthopedics. However, these injections can be quite painful, which leads many patients to discontinue treatment.

Often, the injection involves a mixture of local anesthetic and corticosteroids despite a lack of evidence that the use of lidocaine improves pain. Due to the acidic pH, the lidocaine component of the injection can actually cause a significant burning sensation during the procedure. Lidocaine does not have anti-inflammatory properties and does not treat the underlying pathology. By including another medication, lidocaine also adds cost and risk to the procedure.

The purpose of this study is to see if removing lidocaine from intralesional injections decreases the pain of injection.

Condition or disease Intervention/treatment Phase
Keloid Alopecia Areata Acne Hypertrophic Scar Epidermal Inclusion Cyst Frontal Fibrosing Alopecia Lichen Plano-Pilaris Keratoacanthoma Plaque Psoriasis Lichen Simplex Chronicus Prurigo Nodularis Nummular Eczema Granuloma Annulare Morphea Lichen Planus Drug: Corticosteroid with lidocaine Drug: Corticosteroid with normal saline Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Use of Local Anesthetic in Intralesional Corticosteroid Injections; A Randomized, Double Blind Controlled Trial
Actual Study Start Date : October 1, 2018
Actual Primary Completion Date : September 1, 2019
Actual Study Completion Date : September 1, 2019

Arm Intervention/treatment
Active Comparator: Corticosteroid with lidocaine
This arm will include an injection mixture of corticosteroid and lidocaine
Drug: Corticosteroid with lidocaine
Intralesional corticosteroid injection

Experimental: Corticosteroid with normal saline
This arm will include a mixture of corticosteroid and normal saline. The purpose of normal saline is to keep the volume and concentration similar when compared to the injections containing lidocaine.
Drug: Corticosteroid with normal saline
Intralesional corticosteroid injection

Primary Outcome Measures :
  1. Pain Outcome: Visual Analog Scale [ Time Frame: Assessed 1 minute after the injection (in clinic) ]
    Assessed using the visual analog scale (0-10 scale). Zero indicates no pain, 10 indicates worst pain ever.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • >12 years old presenting with an indication for intralesional steroid injection

Exclusion Criteria:

  • Unconsentable
  • Not a candidate for corticosteroid injection
  • Contraindication to lidocaine

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03630198

Layout table for location information
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37235
Sponsors and Collaborators
Vanderbilt University Medical Center
Layout table for investigator information
Principal Investigator: Brian Drolet, MD Vanderbilt University Medical Center
  Study Documents (Full-Text)

Documents provided by Brian Drolet, Vanderbilt University Medical Center:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Brian Drolet, Assistant Professor, Vanderbilt University Medical Center
ClinicalTrials.gov Identifier: NCT03630198    
Other Study ID Numbers: 181119
First Posted: August 14, 2018    Key Record Dates
Results First Posted: March 11, 2021
Last Update Posted: March 11, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: IPD will not be shared with other researchers

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Brian Drolet, Vanderbilt University Medical Center:
local anesthetic
Additional relevant MeSH terms:
Layout table for MeSH terms
Epidermal Cyst
Alopecia Areata
Lichen Planus
Granuloma Annulare
Cicatrix, Hypertrophic
Skin Diseases, Papulosquamous
Skin Diseases
Hair Diseases
Pathological Conditions, Anatomical
Skin Diseases, Eczematous
Lichenoid Eruptions
Collagen Diseases
Connective Tissue Diseases
Pathologic Processes
Lymphoproliferative Disorders
Lymphatic Diseases
Necrobiotic Disorders
Anesthetics, Local